eISBN: 978-1-68108-391-9
ISBN: 978-1-68108-392-6

eISSN: 2468-5372
ISSN: 2468-5364

Recent Advances in Biotechnology

Volume 3

Recent Progress in Glycotherapy

Editor:
Qun Zhou

Recent Advances in Biotechnology

(Volume 3)

Recent Progress in Glycotherapy

Edited by

Qun Zhou

Protein Engineering,
Biologics Research, Sanofi, Framingham,
Massachusetts 01701,
United States

Recent Advances in Biotechnology

Volume # 3

Recent Progress in Glycotherapy

Editor: Qun Zhou

ISSN (Online): 2468-5372

ISSN: Print: 2468-5364

ISBN (eBook): 978-1-68108-391-9

ISBN (Print): 978-1-68108-392-6

© 2016, Bentham eBooks imprint.

Published by Bentham Science Publishers – Sharjah, UAE. All Rights Reserved.

BENTHAM SCIENCE PUBLISHERS LTD.

End User License Agreement (for non-institutional, personal use)

This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (**"Work"**). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.

Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: permission@benthamscience.org.

Usage Rules:

1. All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.
2. You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it. The following DRM (Digital Rights Management) policy may also be applicable to the Work at Bentham Science Publishers' election, acting in its sole discretion:

- 25 'copy' commands can be executed every 7 days in respect of the Work. The text selected for copying cannot extend to more than a single page. Each time a text 'copy' command is executed, irrespective of whether the text selection is made from within one page or from separate pages, it will be considered as a separate / individual 'copy' command.
- 25 pages only from the Work can be printed every 7 days.

3. The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.

Disclaimer:

Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction,

advertisements or ideas contained in the Work.

Limitation of Liability:

In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.

General:

1. Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of the U.A.E. as applied in the Emirate of Dubai. Each party agrees that the courts of the Emirate of Dubai shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).
2. Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.
3. You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.

Bentham Science Publishers Ltd.
Executive Suite Y - 2
PO Box 7917, Saif Zone
Sharjah, U.A.E.
Email: subscriptions@benthamscience.org

CONTENTS

FOREWORD i

PREFACE ii

LIST OF CONTRIBUTORS iv

CHAPTER 1 VACCINE AND ANTIBODY THERAPY AGAINST THOMSEN-FRIEDENREICH TUMOR-ASSOCIATED CARBOHYDRATE ANTIGENS 3

*Rcwnc"C0Xkfgktc."U{nxckp"Lwnkgp."Nkknkcpc"T0Nqwtgktq."Fkcpc"R0Uqwuc."O{nªpg"C0Ecttcuecn"*cpf *"Rjknkrrg"Fgrcppq{*

INTRODUCTION 4

Structure and Biosynthesis of Thomsen–Friedenreich Antigens 4

Expression of Thomsen–Friedenreich Antigens in Cancers 8

T Antigen 8

Tn Antigen 8

Sialyl-Tn Antigen 8

GENERAL ASPECTS OF IMMUNE RESPONSE AGAINST CARBOHYDRATE ANTIGENS 9

ANTICANCER VACCINES 11

Vaccines Against Thomsen–Friedenreich Antigens 13

Theratope and Other Monovalent Vaccines 13

Multiantigenic Vaccines 17

Structurally Modified Mimetic Vaccines 18

Self-Adjuvanting Vaccines 21

ANTIBODY BASED THERAPY AGAINST TF-ANTIGENS 22

Therapeutic Antibodies in Cancer 22

Therapeutic Antibodies Against Tn and STn Antigens 23

T Antigen and Anti-T mAbs 24

Tn Antigen and Anti-Tn mAbs 26

STn Antigen and Anti-STn mAbs 26

Future Perspective 27

CONCLUSION 27

CONFLICT OF INTEREST 28

ACKNOWLEDGEMENTS 28

REFERENCES 28

CHAPTER 2 CELL SURFACE GLYCANS AS VIRAL ENTRY FACTORS AND TARGETS FOR BROADLY ACTING ANTIVIRALS 39

*Ejg"E0Eqnrkwu"*cpf *"Vjqocu"H0Dcwogtv*

INTRODUCTION 40

GLYCAN STRUCTURE 40

HEPARAN SULFATE-BINDING VIRUSES 41

SIALIC ACID-BINDING VIRUSES 44

GLYCANS AS ANTIVIRAL TARGETS 45

Inhibitors of HS-Binding Viruses 45

Inhibitors of SA-Binding Viruses 47

Inhibitors of Both HS- and SA-Binding Viruses 48

PERSPECTIVES 48

CONFLICT OF INTEREST 49

ACKNOWLEDGEMENTS 49

REFERENCES 49

CHAPTER 3 CARBOHYDRATE PEGYLATION IN CHEMOTHERAPY 60

Tqucrkc"Ci wuvk."O0'Gwi gpkc"I kqt i k'cpf "Tquc"O0'f g'Ngf gtmgo gt

INTRODUCTION 61

SUGAR-PEGYLATION OF PROTEINS 66

GlycoPEGylation 66

Glycation of Proteins for Further PEGylation 68

PEGylation of Native Glycoproteins 68

Localization of O-GlcNAc Glycosylation in a Protein by PEGylation 70

PEGYLATION FOR GLYCAN DELIVERY 71

Small Sugar-Based Drugs 71

Polysaccharidic Drugs 73

PEGYLATED POLYSACCHARIDES FOR DRUG/GENE DELIVERY 75

Chitosan 75

Dextran 77

Carboxymethyldextran (CMD) 79

Glucans 80

TARGETED DRUG/GENE DELIVERY 82

Galactose/Lactose Decorated Target Delivery Systems 83

Use of Galactose or Lactose p-Aminophenyl-β-D-Glycoside 83

Use of Lactobionic Acid 86

Use of 2-Amino-2-Deoxy-D-Galactose 87

β-Galactosylation by Other Methods 88

Mannose-Decorated Target Delivery Systems 89

CONCLUDING REMARKS 91

CONFLICT OF INTEREST 91

ACKNOWLEDGEMENTS 92

REFERENCES 92

CHAPTER 4 RECENT DEVELOPMENTS IN HYALURONIC ACID-BASED NANOMEDICINE 102

Cppc"O gtq."Cpvqpgnc"I tki qngwq."I cdtkgng"Octvkpg/"cpf "I kcphtcpeq"Rcuw

INTRODUCTION 103

General Introduction of Hyaluronic Acid 103

HA-Drug Conjugates 106

HA–Peptide Conjugates 113

HA-Protein Conjugates 115

CONCLUSION 122

CONFLICT OF INTEREST 123

ACKNOWLEDGEMENTS 123

REFERENCES 123

CHAPTER 5 UTILIZATION OF GLYCOSYLATION ENGINEERING IN THE DEVELOPMENT OF THERAPEUTIC PROTEINS 130

Tqdgtv"[kvg"Ej qw."Mgxkp"D0'Vwtpgt "cpf "J wkwcp"Nk

INTRODUCTION 130

The Processes of N- and O-linked Glycosylation 131

Glycosylation Engineering 133

Glycosylation Analysis of glycoproteins 134

Glycosylation Related to Half-Life 136

Glycosylation Effects on PD 141

CONCLUDING REMARKS 143

CONFLICT OF INTEREST 143

ACKNOWLEDGEMENTS 143

REFERENCES 144

CHAPTER 6 ANTIBODY ENGINEERING THROUGH FC GLYCANS FOR IMPROVED THERAPEUTIC INDEX 152

S wp"\ j qw"cpf "J wcy gk"S kw

INTRODUCTION 153
GLYCOENGINEERING FOR ENHANCED ANTIBODY EFFECTOR FUNCTION 155
GLYCOENGINEERING FOR ENHANCED ANTIBODY ANTI-INFLAMMATORY ACTIVITY 159
GLYCOENGINEERING FOR SITE-SPECIFIC ANTIBODY CONJUGATION 161
CONCLUSION 163
CONFLICT OF INTEREST 164
ACKNOWLEDGEMENTS 164
REFERENCES 164

CHAPTER 7 ENGINEERING OF THERAPEUTIC PROTEINS THROUGH HYPERGLYCOSYLATION 172

Pcvcnkc"Egcirkq."Octkpc"Gvej gxgttkic c{."Tkecf q"Mtcvlg"cpf "Octequ"Qi i gtq

INTRODUCTION 173
PROPERTIES CONFERRED TO PROTEINS BY GLYCANS 174
Effects of Glycosylation on Solubility and Stability of Glycoproteins 174
Effects of Glycosylation on Bioactivity of Glycoproteins 175
Effects of Glycosylation on Antigenicity and Immunogenicity 175
Effects of Glycosylation on Pharmacokinetics and in vivo Clearance 176
INCREASING THE EFFICACY OF RECOMBINANT PROTEIN-BASED THERAPIES THROUGH GLYCOSYLATION ENGINEERING 177
ENGINEERING OF PROTEINS THROUGH HYPERGLYCO-SYLATION 180
Engineering of Proteins through the Addition of N-glycans 180
Factors Affecting N-glycosylation Efficiency 180
Approaches to Incorporate New N-glycan Moieties into Proteins 183
Engineering of Proteins through the Incorporation of O-glycans 186
General Aspects of O-glycosylation in Eukaryotes 186
Strategies to Introduce Potential O-glycosylation Sites 189
HYPERGLYCOSYLATION OF HIFN-A2B AS AN EMBLEMATIC CASE 191
N-glycoengineering of hIFN-α2b 192
O-glycoengineering of hIFN-α2b 196
CONFLICT OF INTEREST 198
ACKNOWLEDGEMENTS 198
REFERENCES 199

SUBJECT INDEX 209

FOREWORD

This book includes a timely collection of topics addressing important advances in glycotechnology that are being exploited in the development of glycotherapeutics.

This area is rooted in the rich history of the chemistry of carbohydrates that contributed to defining the structures of oligosaccharides and developed the complex synthesis of these exquisite molecules. In addressing the functions of these structures in animal cells glycobiologists, using the major advances in biochemistry and molecular biology developed in the last decades of the 20th century, unraveled the complex process involved in the biosynthesis, assembly, and processing of glycoproteins, glycolipids and proteoglycans. One of the seminal observations that initiated the general area of glycobiology was Victor Ginsburg's discovery in the early 1960's that neuraminidase digestion of lymphocytes altered their normal trafficking pattern, which ultimately led to the discovery of the animal cell lectins, and we now know that the functions of mammalian cell glycans are somehow associated with either direct or indirect protein-glycan interactions making them ideal candidates for glycotherapeutic studies with many examples already available.

The obvious challenge now resides in the continued search for the roles of glycans in normal physiology and disease; and these advances a coming rapidly in the field we now refer to as Glycomics, which has recently been recognized as a strategic area for NIH Common Fund support. The future is indeed bright, and the opportunities are ripe for the investigators to exploit this rapidly expanding area for glycotherapy.

Dr. David F. Smith
Emory Comprehensive Glycomics Core
Emory University School of Medicine
Atlanta, GA 30322
USA
E-mail: dfsmith@emory.edu

PREFACE

There are many therapies being developed through biotechnology for treating diseases. They include protein therapy, gene therapy, cell therapy, and glycotherapy. As one of the important disease treatment approaches, glycotherapy provides solution for some unmet medical needs using glycoengineering. It has been used in clinics for decades.

Heparin, a glycosaminoglycan and blood thinner, acts as an anticoagulant and is one of World Health Organization's lists of essential medicines. The sialic acid analogues, oseltamivir and zanamivir, are widely used anti-influenza drugs. Polysaccharide vaccines including Menactra, Prevnar, and Typhim Vi, have been used to stimulate immunity against infection. In addition to therapy using sugar or sugar analogues, therapeutic proteins, such as darbepoetin alfa and imiglucerase, are also generated using glycoengineering *in vivo* or *in vitro* to enhance therapeutic index.

During the last two decades, significant progress has been made in glycotherapy with glycoengineering and glycan mimics although there are many challenges. The glycans are chemoenzymatically modified or conjugated to small molecular weight drugs, proteins, and nucleic acids for increasing pharmacokinetics and pharmacodynamics. Although there is an excellent review published recently by Hudak and Bertozzi (Chemistry & Biology 2014), glycotherapy has not been extensively appreciated in books and unknown to many readers outside this particular field. The current book attempts to fill the gap and provide more recent information related to the exciting progress in this important area of biotechnology.

The book includes reviews on glycotherapy which focus on modification of protein or small molecular weight drug using recombinant and chemoenzymatic approaches. The progress on bioconjugation of glycan using hydrophilic polymers is also covered.

Chapters 1 and 2 focus on the development of vaccines and antibodies against tumor-associated carbohydrate antigen for cancer treatment, as well as the use of glycan for viral inhibition. Chapters 3 and 4 describe the progress in glycoPEGylation and hyaluronic acid conjugation for increasing therapeutic index in treating diseases. The glycoengineering of therapeutic proteins is reviewed in chapters 5, 6 and 7. They provide overviews of recent advances in modification of glycans in proteins or antibodies using recombinant, chemoenzymatic or bioconjugation methods.

Although only a few topics of glycotherapy are being reviewed here, this book aims to provide readers with overview of the researches which have been actively pursued during recent years. We expect to have more excellent books or reviews on this important therapeutic

area in the future.

Dr. Qun Zhou
Protein Engineering
Global BioTherapeutics, Sanofi, Framingham
Massachusetts 01701
United States

List of Contributors

Anna Mero	Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
Antonella Grigoletto	Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy
Che C. Colpitts	Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France. Université de Strasbourg, 67000 Strasbourg, France
Diana P. Sousa	UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Portugal.
Gabriele Martinez	Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
Gianfranco Pasut	Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy. Veneto Institute of Oncology IOV-IRCCS, Padova, Italy
Huawei Qiu	Protein Engineering, Sanofi, 5 Mountain Road, Framingham, MA 01701, United States
Huijuan Li	Moderna Therapeutics 200 Technology Square Cambridge, MA 02139, USA
Kevin B. Turner	Sterile Product and Analytical Development, Biologics and Vaccine Development, Merck & Co., Inc., Kenilworth, NJ USA
Liliana R. Loureiro	UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Portugal.
Marcos Oggero	UNL, CONICET, Cell Culture Laboratory, FBCB. Edificio FBCB-Ciudad Universitaria UNL. C.C. 242. (S3000ZAA) Santa Fe., Argentina
Marina Etcheverrigaray	UNL, CONICET, Cell Culture Laboratory, FBCB. Edificio FBCB-Ciudad Universitaria UNL. C.C. 242. (S3000ZAA) Santa Fe., Argentina
M. Eugenia Giorgi	CIHIDECAR-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
Mylène A. Carrascal	UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Portugal.
Natalia Ceaglio	UNL, CONICET, Cell Culture Laboratory, FBCB. Edificio FBCB-Ciudad Universitaria UNL. C.C. 242. (S3000ZAA) Santa Fe., Argentina
Paula A. Videira	UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Portugal. Univ. Lille, Inserm, U908 - CPAC - Cell Plasticity and Cancer, F-59000 Lille, France

Philippe Delannoy	Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France
Qun Zhou	Protein Engineering, Sanofi, 5 Mountain Road, Framingham, MA 01701, United States
Ricardo Kratje	UNL, CONICET, Cell Culture Laboratory, FBCB. Edificio FBCB-Ciudad Universitaria UNL. C.C. 242. (S3000ZAA) Santa Fe., Argentina
Robert Yite Chou	Sterile Product and Analytical Development, Biologics and Vaccine Development, Merck & Co., Inc., Kenilworth, NJ USA
Rosa M. de Lederkremer	CIHIDECAR-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
Rosalia Agusti	CIHIDECAR-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina
Sylvain Julien	Univ. Lille, Inserm, U908 - CPAC - Cell Plasticity and Cancer, F-59000 Lille, France
Thomas F. Baumert	Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France. Université de Strasbourg, 67000 Strasbourg, France. Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France

CHAPTER 1

Vaccine and Antibody Therapy Against Thomsen-Friedenreich Tumor-Associated Carbohydrate Antigens

Paula A. Videira[1,2,*], **Sylvain Julien**[2], **Liliana R. Loureiro**[1], **Diana P. Sousa**[1], **Mylène A. Carrascal**[1] and **Philippe Delannoy**[3,*]

[1] *UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Portugal*

[2] *Univ. Lille, Inserm, U908 - CPAC - Cell Plasticity and Cancer, F-59000 Lille, France*

[3] *Univ. Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000 Lille, France*

Abstract: The Thomsen Friedenreich (TF) carbohydrate antigens are a group of short *O*-glycans overexpressed on most carcinomas that have been correlated with cancer progression and poor prognosis. Usually associated with immunosuppressive tumor environment, there is a number of potential immunotherapeutics against TF antigens have been developed, which comprise vaccines and antibodies. As therapeutic vaccination, TF antigens already entered into clinical trials, but with limited success due to low patient's response. Novel vaccine design, with multiantigenicity and pointing towards the cellular immune responses arises as a potent stratagem to overcome the low ability of TF antigens to boost immune responses, typical of carbohydrates. The development of antibodies against TF antigens boosted even before vaccine development. These are mainly used for diagnostics, but so far no such antibody entered into clinical trials in patients. Increasing the specificity and the therapeutic efficiency of existing antibodies and developing novel antibodies are still necessary. The vast array of methodologies and engineering techniques available today will allow rapid development and novel formats for both vaccines and antibodies.

* **Corresponding authors Paula Videira:** UCIBIO, Departamento de Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de 2829-516 Caparica, Portugal; Tel: +351 968169892; E-mail: p.videira@fct.unl.pt, **Philippe Delannoy:** Université de Lille - Sciences et Technologies Unité de Glycobiologie Structurale et Fonctionnelle (UGSF) UMR CNRS 8576, Bât. C9 - 59655 Villeneuve d'Ascq, France; Phone +33 (0)3 20436923; E-mail: philippe.delannoy@univ-lille1.fr

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

Vaccines and antibodies targeting the same epitopes can function in synergy both to protect and to clear patient's cancer cells. Whilst on one hand, TF antigens dampen immune responses against tumor cells, it is anticipated that the challenge is overcome by applying our increasing knowledge of the mechanisms behind to improve molecular design. Novel solutions are also envisaged by combining anti-TF therapies with other immunotherapies.

Keywords: Clinical trials, Glycan-based vaccines, IgG, Immune response, Immunological memory, Immunotherapy, Mimetic vaccines, Monoclonal antibodies, Mucins, O-glycans, Self-adjuvanting vaccines, Sialic acid, Sialyl-Tn antigens, T antigen, Therapeutic antibodies, Theratope, Thomsen Friedenreich antigens, Tn antigen, Tumor associated carbohydrates.

INTRODUCTION

Structure and Biosynthesis of Thomsen–Friedenreich Antigens

Thomsen–Friedenreich antigens are *O*-linked carbohydrate antigens found on membrane glycoproteins, especially on serine and threonine rich and tandem repeated domains of mucins [1]. The Thomsen–Friedenreich antigens are originated during the first steps of mucin glycosylation, resulting from a defect in the elongation of *O*-glycan chains in cancer cells.

The first described Thomsen-Friedenreich antigen (called T or TF antigen) was initially found on red blood cells and consists in the disaccharide Galβ1-3GalNAc α-linked to serine or threonine residue (Galβ1-3GalNAcα1-Ser/Thr), forming the core 1 structure of mucin *O*-glycans. T antigen is normally the precursor of core 2 *O*-glycans but can be unmasked when cancer cells have lost the ability to synthesize the core 2 (Fig. **1**). The second described TF antigen called Tn antigen is the cryptic precursor of the core 1 and consists in the single *N*-acetyl-galactosamine (GalNAc) residue α-linked to serine or threonine residue (GalNAcα1-Ser/Thr) that can remain unmasked if the ability to synthesize core 1 is lost (Fig. **1**) [2]. The expression of Tn antigen on blood cells is responsible for the Tn-syndrome, which is a rare autoimmune hematological disorder [3]. The Tn antigen can be also sialylated on C6 position of GalNAc, resulting in the disaccharide Neu5Acα2-6GalNAcα1-Ser/Thr, known as sialyl-Tn (STn) antigen.

STn is almost absent in normal healthy tissues but can be detected at various frequencies in almost all kind of carcinomas [4].



Fig. (1). Biosynthesis of *O*-glycan chains in normal and cancer cells. The figure illustrates mechanisms by which *O*-glycans expressed in normal cells can be turned down to Thomsen–Friedenreich antigens (T, Tn and STn antigens). Gal: Galactose, GalNAc: *N*-acetyl-galactosamine, GlcNAc: *N*-acetyl-glucosamine, Neu5Ac: *N*-acetyl-neuraminic acid, Fuc: Fucose.

The biosynthesis of mucin *O*-glycan chains is a step-by-step process occurring in the Golgi apparatus. *O*-glycans are synthesized by the sequential action of several glycosyltransferases, each transferring a monosaccharide *e.g.*, *N*-acetyl-galactosamine (GalNAc), galactose (Gal), *N*-acetyl-glucosamine (GlcNAc), or *N*-acetyl-neuraminic acid (Neu5Ac) from a donor nucleotide-sugar (*e.g.*, UDP-GalNAc, UDP-Gal, UDP-GlcNAc or CMP-Neu5Ac) to an acceptor that is the glycan being synthesized. Glycosyltransferases are membrane-bound enzymes of which the level of expression, substrate specificity and localization in Golgi compartments are responsible for the pattern of *O*-glycans expressed in a given cell or carried by a given glycoprotein. The initiation step is the transfer of a GalNAc residue on a serine or a threonine of the tandem repeat sequences of

CHAPTER 2

Cell Surface Glycans as Viral Entry Factors and Targets for Broadly Acting Antivirals

Che C. Colpitts[1,2,*] and **Thomas F. Baumert**[1,2,3,*]

[1] *Inserm, U1110, Institut de Recherche sur les Maladies Virales et Hépatiques, 67000 Strasbourg, France*

[2] *Université de Strasbourg, 67000 Strasbourg, France*

[3] *Institut Hospitalo-Universitaire, Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg, 67000 Strasbourg, France.*

Abstract: Cellular glycans play key roles in the infection process of many human viruses. Viral attachment to heparan sulfate (HS) or sialic acid (SA) moieties in cell surface glycans is a critical and conserved step for the entry of many human viruses, including clinically important human pathogens such as hepatitis B virus, hepatitis C virus, human immunodeficiency virus and influenza virus. As such, glycans are attractive targets for broadly acting antivirals. Molecules that mimic HS or SA interfere with viral attachment by competing for binding of virion glycoproteins to cellular glycans. Modulation of the levels of cellular glycans also affects viral attachment. These approaches show great promise based on their broad-spectrum activities, but the molecules identified so far often possess undesirable pharmacological properties resulting in potential adverse effects. Here, we describe the mechanisms involved in glycan binding, discuss broadly acting glycan-targeted antiviral strategies, and provide perspectives for the rational design of broad-spectrum small molecule entry inhibitors with broad-spectrum activities and appropriate pharmacological properties.

Keywords: Antivirals, Broad-spectrum antiviral therapy, Chemical biology, Glycan mimetics, Glycosaminoglycans, Glycotherapy, Heparan sulfate proteoglycans, Heparin, Hepatitis B virus, Hepatitis C virus, Herpes simplex virus,

[*] **Corresponding authors Thomas F. Baumert:** Université de Strasbourg, 67000 Strasbourg, France; Tel: +33 3 68 85 37 03; Fax: +33 3 68 85 37 24; E-mail: thomas.baumert@unistra.fr and **Che C. Colpitts:** Université de Strasbourg, 67000 Strasbourg, France; Tel: +33 3 68 85 37 38; Fax: +33 3 68 85 37 24; E-mail: colpitts@unistra.fr

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

Human immunodeficiency virus, Influenza virus, Polyphenols, Sialic acid, Sialoglycans, Small molecule entry inhibitors, Viral attachment, Viral entry, Virus-host interactions.

INTRODUCTION

Cell surface glycans mediate the initial infection steps of many pathogens, including most human viruses. An overwhelming majority of these viruses initiate infection of their target cells by low-affinity binding to cell surface glycans, such as glycosaminoglycans (GAGs) or sialoglycans (SGs). GAGs and SGs are ubiquitous on cells, and many microbes have evolved to exploit them for initial attachment to their target cells [1]. Among the GAGs, heparin/heparan sulfate (HS) is the most commonly used viral attachment site. The high density of cell-surface HS allows microbes to bind and increase their concentration at the cell surface to facilitate subsequent entry and infection steps. Other viruses recognize and bind to sialic acid (SA), which is abundantly expressed in SGs on the cell surface [2]. These interactions with glycans are critical to capture virions from extracellular spaces and concentrate them in the vicinity of other entry factors and signalling molecules to allow high affinity binding and uptake into the cell. As such, glycans represent attractive targets for broad-spectrum antiviral therapies.

GLYCAN STRUCTURE

GAGs are unbranched polysaccharides comprised of repeating disaccharide units of an amino sugar (*N*-acetylglucosamine or *N*-acetylgalactosamine) and either a uronic sugar (either glucuronic acid or iduronic acid) or galactose [3] and usually linked to proteins *via* *O*-linked or *N*-linked glycosylation. GAGs are classified into four groups that reflect the composition of the disaccharide unit. These include (HS), chondroitin/dermatan sulfate, keratan sulfate or hyaluronic acid [4]. The repeating disaccharide unit of GAGs is variably sulfated [5], leading to high diversity and complexity and allowing for specific binding with distinct GAG-binding proteins. Indeed, interactions between GAGs and a diverse spectrum of GAG-binding proteins regulate many biological processes, including cell growth and proliferation pathways, cell adhesion or migration, and tissue hydration [4]. GAG-binding proteins interact with negatively charged sulfates and carboxylates in GAGs *via* a binding pocket of positively charged basic amino acids. A

consensus sequence of XBBXBX or XBBBXXBX (where B is a basic lysine or arginine residue) is typically found in proteins that bind to HS [6]. Binding affinity depends on the overall shape and conformation of GAGs and is affected by the number and orientation of the sulfate group charges [3].

SGs are a distinct group of cellular glycans, comprised of (SA) attached to the termini of *N*-linked and *O*-linked glycans. The carboxylate group at the 1-carbon position of SA is ionized at physiological pH, allowing for interactions with basic residues of saccharide-binding proteins such as lectins [7]. Binding between SGs and SG-binding proteins is predominantly mediated by extensive hydrogen bonding between the carboxylate, hydroxyls and N-acetyl group of SA and polar amino acid residues.

HEPARAN SULFATE-BINDING VIRUSES

A large and diverse group of human viruses bind to HS proteoglycans, *via* interactions between viral glycoproteins and negatively charged HS moieties in cellular GAGs. These viruses are summarized in Table **1**. Most hepatotropic viruses such as hepatitis C virus (HCV) [8 - 10], hepatitis B virus (HBV) and its satellite, hepatitis D virus [11 - 14], as well as hepatitis E virus [15], require a primary attachment step to HS. Moreover, other viruses that infect a wide range of cell types similarly require HS for binding. These include viruses with RNA genomes, such as human immunodeficiency virus (HIV) [16], dengue virus [17], filoviruses [18], Sindbis virus (SINV) [19], respiratory syncytial virus (RSV) [20 - 22] and other paramyxoviruses [23, 24], Rift Valley fever virus [25], severe acute respiratory syndrome-associated coronavirus [26], as well as DNA viruses, including herpes simplex virus 1 and 2 (HSV-1/-2) [27 - 30], human cytomegalovirus (CMV) [31], varicella zoster virus [32], human herpesvirus 8 [33, 34], vaccinia virus (VACV) [35], adenovirus (AdV) types 2 and 5 [36, 37], some strains of norovirus [38] and human papillomavirus (HPV) [39]. Merkel cell virus initially interacts with HS-containing GAGs, although SA is also required [40]. Other viruses, including the rhabdovirus vesicular stomatitis virus (VSV), are thought to also require HS for binding [41], although the specific details of the interactions remain unclear.

CHAPTER 3

Carbohydrate PEGylation in Chemotherapy

Rosalia Agusti, M. Eugenia Giorgi and **Rosa M. de Lederkremer**[*]

Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Centro de Investigación en Hidratos de Carbono (CIHIDECAR), Facultad de Ciencias Exactas y Naturales, Buenos Aires, Argentina

Abstract: Improvement of drug delivery by covalent modification with polyethylene glycol (PEG) has been widely applied to proteins and low molecular weight pharmaceuticals. Protein therapeutic agents have the drawback of short circulating half-life due to their lability towards proteolytic enzymes and rapid clearance by kidney filtration. Moreover, their recognition by the immune system results in the production of neutralizing antibodies. Several strategies have been used for the PEGylation of proteins at the amino group of lysine but the product is heterogeneous due to random PEGylation. More recently, selective PEGylation of proteins was achieved by introduction of a PEGylated carbohydrate in an *O*-glycosylation site. This technique is called glycoPEGylation and is used for the production of several therapeutics, some of them are currently in advanced clinical trials. Improvement of the delivery system rather than the drug itself has led to the optimization of the therapeutic properties of existing drugs by minimizing their side effects. In this respect, active targeting to receptors present in cancer tissues prevents healthy ones from being damaged. Since carbohydrates have been recognized as playing an important role in the interaction with cell receptors, PEGylated carbohydrates have been used for active targeting of drugs. In this review we discuss different applications of sugar-PEGylation.

Keywords: Active targeting, Bioavailability, Carbohydrates, Chemotherapy, Drug carriers, Drug delivery, Gene delivery, Gene therapy, Glycan delivery, GlycoPEGylation, Ligands, Multiarm PEGs, O-GlcNAc quantification, PEG, PEG-sialic acid, PEGylated nanoparticles, PEGylated polysaccharides,

[*] **Corresponding author Rosa M. de Lederkremer:** CIHIDECAR-CONICET, Departamento de Química Orgánica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina; Tel/Fax: 54-1--45763352; E-mail: lederk@qo.fcen.uba.ar

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

PEGylation, siRNA, Sugar PEGylation, Targeted delivery.

INTRODUCTION

Bioavailability of drugs in circulation remains a crucial issue in chemotherapy since most of them are degraded by metabolic processes or are poorly soluble in aqueous systems. The most well-established and widely employed way to increase their circulation half-life without affecting their activity is by conjugation with a water soluble biocompatible polymer. In this regard, poly(ethyleneglycol) (PEG) has been extensively used due to its lack of toxicity and immunogenicity. These characteristics earned PEG its approval by the United States Food and Drug Administration (USFDA) for its use as excipient in pharmaceutical formulas [1].



Fig. (1). Types of PEG used for the derivatization of drugs and proteins.

PEG reagents are commercially available in different lengths, shapes and chemistries, allowing them to react with particular functional groups for their covalent attachment. PEGs may be arranged in linear or branched structures, including multiarm PEGs designed to increase the loading of the active molecule (Fig. **1**).

PEG derivatives were first developed for the attachment to the amino groups in proteins [2] and bovine serum albumin was one of the first to be linked to a methoxypolyethylen glycol (mPEG) chain [3]. In this and some other early works the amino groups at the N terminus or in lysine side chains were used for PEG attachment with activated carboxyl or aldehyde functionalized PEGs. Currently, there are many monofunctional and homo and heterobifunctional PEGs available in the market for amide linking including *N*-hydroxysuccinimidyl esters (PEG-NHS), carboxylic acids (PEG-COOH) for *in situ* activation with carbodiimide (EDC or DCC), and *p*-nitrophenylcarbonates (PEG-NPC) (Fig. **2**).



Fig. (2). PEG derivatives for conjugation with drugs.

However, the abundance of lysine and its usual surface location lead to complex mixtures differing in the number and site of PEGylation [4]. To avoid these shortcomings, PEGylation has evolved towards site-specific amino acid

CHAPTER 4

Recent Developments in Hyaluronic Acid-Based Nanomedicine

Anna Mero[1], **Antonella Grigoletto**[1], **Gabriele Martinez**[2] and **Gianfranco Pasut**[1,2,*]

[1] *Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via F. Marzolo 5, 35131 Padova, Italy*

[2] *Veneto Institute of Oncology IOV-IRCCS, Padova, Italy*

Abstract: Originally considered simply another naturally occurring component of a number of tissues, breakthrough findings later disclosed hyaluronan's (HA) extraordinary biological properties and paved the way for a new era of HA-associated medical applications. HA is, in fact, recognized by many cellular receptors, it can mediate cell migration, proliferation, cell-cell aggregation, it has been shown to promote angiogenesis, *and the list goes on.* This plethora of activities initially moved attention away from a polymer that was considered a simple carrier of biomolecules and towards its potential use in both treating many diseases and conditions and being involved in drug delivery. Given these premises, medical applications exploiting HA's different roles have been developed. The focus of this chapter is directed towards the chemical conjugation of HA with small drugs, peptides and proteins. Reviewing the vast body of literature dedicated to this field, an extraordinary range of applications will be outlined. Although HA cannot be considered a polymer that is appropriate for all uses, conjugates specifically designed to exploit some of its biological properties and for numerous specific applications will no doubt enjoy an advantage over other polymeric conjugates.

Keywords: Anti-TNF-α, Anticancer drug, Anticancer therapy, CD44, Doxorubicin, Drug conjugates, Drug delivery, Human growth hormone, Hyaluronan, Hyaluronic acid, Insulin, Interferon alpha, Osteoarthritis, Paclitaxel,

[*] **Corresponding author Gianfranco Pasut:** Department of Pharmaceutical and Pharmacological Sciences, University of Padova, *Via* F. Marzolo 5, 35131 Padova, Italy; Tel: 617-209-5850; Fax: 617-583-1998; E-mail: gianfranco.pasut@unipd.it

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

Polymer conjugation, Polysaccharide, Protein conjugation, Protein delivery, RHAMM, RNase A, SN38.

INTRODUCTION

The term "polymer therapeutics" was coined by Ruth Duncan in the 1990s to describe families of polymer constructs to which a drug is covalently bound [1]. This class of substances, which falls under the definition of "new chemical entities", can be distinguished from those drug delivery systems that "per se" only entrap a free drug. Polymer-drug conjugates, polymer-protein/peptide conjugates, polymer-oligonucleotide conjugates, polymeric drugs and block-copolymer-drug micelles all represent sub-classes of polymer therapeutics. Already in 1975, Helmut Ringsdorf introduced the concept of polymer-drug conjugates and the idea of exploiting polymers to increase the solubilization of hydrophobic drugs, to protect drugs from degradation, to prolong their pharmacokinetic profile, and to achieve controlled delivery to cells, tissues and/or organs [2]. Among the several polymers that have been extensively studied, polyethylene glycol (PEG) has proved to be one of the most successful in view of its wide applicability. It has, in fact, already yielded numerous products widely and commonly used in clinical practice such as conjugates with proteins, peptides and oligonucleotides or PEG-modified liposomes [3]. PEG has made a significant contribution to polymer therapeutics, and several new polymers and their derivatives are presently being investigated in the context of preclinical and clinical trials as interest in the development of biodegradable polymers continues to grow. Just a few examples are polyglutamic acid [4], dextrin [5], hyaluronic acid [6], hydroxyethyl starch [7] and polysialic acid [8].

This chapter, which focuses on hyaluronic acid and its conjugates, aims to highlight recent advances in the study of a polymer that can be the carrier for drugs, proteins, and peptides.

General Introduction of Hyaluronic Acid

Hyaluronic acid hyaloid (vitreous) + uronic acid (HA) was isolated for the first time in 1934 from the vitreous humor of cows' eyes by Karl Meyer and John

Palmer [9]. The naturally occurring linear polysaccharide has repeating units of D-glucuronic acid and *N*-acetyl-D-glucosamine disaccharide (Fig. **1**).



Fig. (1). Publications and citations concerning 'Hyaluronic acid AND drug delivery'. Source: PubMed.

The pK_a of HA's carboxyl groups is therefore 3–4; at pH = 7, the carboxyl groups are predominantly ionized and the polymer is a polyanion that has associated cations (the counterions) and thus referred to as hyaluronan. Found in nature in a wide range of molecular weights (from 20kDa to 4000kDa), HA is a highly hydrophilic polymer that can absorb great quantities of water and expand up to 1000 times its solid volume, forming a loose hydrated network [10].

Hyaluronic acid is present in all vertebrates and in several districts of the human body. It is estimated that the adult human body contains about 12-15 g of hyaluronan, almost half of which is located in the skin [11]. It is also found in the synovial fluid, in the vitreous body of the eye, and it plays an important role in a variety of biological processes: it helps to maintain the viscoelasticity of liquid connective tissues and is involved in controlling tissue hydration, water transport, the organization of the extracellular matrix (ECM) and in tissue repair.

CHAPTER 5

Utilization of Glycosylation Engineering in the Development of Therapeutic Proteins

Robert Yite Chou[1], **Kevin B. Turner**[1] and **Huijuan Li**[2,*]

[1] *Sterile Product and Analytical Development, Biologics and Vaccine Development, Merck & Co., Inc., Kenilworth, NJ USA*

[2] *Moderna Therapeutics 200 Technology Square Cambridge, MA 02139, USA*

Abstract: Biologics are drugs made from complex molecules manufactured using living microorganisms, plant or animal cells. Many biologics are produced using recombinant DNA technology. Glycoproteins represent a major portion of biologics, including monoclonal antibodies, Fc-fusion proteins and other therapeutic proteins or enzymes. A thorough understanding of the nature and function of the carbohydrate moiety and its impact on pharmacology properties is essential in discovering, developing and manufacturing safe and efficacious glycoprotein biopharmaceuticals. This review summarizes the recent development in glycosylation engineering and characterization methodology. Examples of *N*-linked and/or *O*-linked glycosylation impacting drug pharmacology properties (including activity, pharmacokinetics, clearance, and immunogenicity) of marketed and developing therapeutic proteins are presented.

Keywords: ADCC, CHO, Fc-fusion, Fluorescence, Fucose, Glycan release, Glycoengineering, Glycoprotein, Glycosylation, Half-life, HILIC, HPLC, IgG, mAbs, Mass spectrometry, PAD, Pharmacodynamics, Pharmacokinetics, Recombinant human erythropoietin, Sialic acids.

INTRODUCTION

Achieving optimum therapeutic efficacy is dependent on maintaining a proper

[*] **Corresponding author Huijuan Li:** Moderna Therapeutics 200 Technology Square Cambridge, MA 02139, USA; Tel: 617-209-5850; Fax: 617-583-1998; E-mail: huijuan.li@modernatx.com

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

balance between drug exposure and its pharmacological effects. Therefore, the PK and PD parameters for therapeutics are often tuned through the drug design in a manner assuring that desired *in vivo* responses are achieved. PK refers to “what body does to the drug” and is influenced by drug absorption, distribution, metabolism and excretion, represented primarily by clearance rates, circulatory half-lives, volumes of distribution, and bioavailability. PD examines “what drug does to the body” and is influenced by the drug exposure and the drug pharmacological activities upon binding to the targets.

As a result of the intrinsic susceptibility of proteins to clearance mechanisms, protein drugs generally display limited plasma persistence. This can be overcome with higher protein concentrations and increased dosing frequencies. However, frequent treatment schedules coupled with the high target specificities and potencies can lead to unsuitably sharp dose/response profiles. The overstimulation of a targeted pathway can trigger autoregulatory feedback inhibition mechanisms that can lead to loss of *in vivo* efficacy. To overcome these limitations it has become routine practice to engineer the physicochemical and pharmacological properties of protein drugs in the early development.

Established technologies, such as targeted mutations, generation of fusion proteins and conjugates, glycosylation engineering, and pegylation, have been shown to significantly improve the efficacy of protein drugs by increasing their molecular stabilities and plasma persistence and consequently improving overall *in vivo* PD responses. Of these, engineered glycosylation is one of the most promising due to the fact that it has been shown to simultaneously improve the parameters necessary for therapeutic efficacy while maintaining target specificity.

The Processes of *N*- and *O*-linked Glycosylation

N-linked glycosylation is a post-translational modification that is conserved across eukaryotes. *N*-glycosylation begins in the endoplasmic reticulum (ER) with the transfer of a preassembled dolichol phosphate-linked fourteen sugar oligosaccharide to targeted asparagine residues in a protein [1, 2]. The preferred site for *N*-glycosylation contains the three amino acid sequence, Asn-Xaa-Ser/Thr where the second position can be any amino acid except Pro. This initial glycan

transfer reaction is catalyzed by the heteromeric oligosaccharyltransferase (OST) complex and is supposed to precede folding of the protein in the ER [3]. Immediately after the oligosaccharide transfer, the two terminal glucose residues are cleaved off by α-glucosidase I and II and the resulting polypeptide with mono-glucosylated glycan structures ($Glc_1Man_9GlcNAc_2$) can interact with the ER-resident membrane-bound lectin calnexin or its soluble homolog calreticulin. These lectins support protein folding in a glycan-dependent protein quality control cycle. Secretory glycoproteins that have acquired their native conformation are released from the calnexin/calreticulin cycle and exit the ER to the Golgi apparatus. In the Golgi, the ER-derived oligomannosidic *N*-glycans on maturely folded glycoproteins are subjected to further *N*-glycan processing which generates the highly diverse complex N-glycans with different functional properties.

In contrast, *O*-linked glycosylation involves the covalent attachment of a monosaccharide to a Ser or Thr residue. Sequence specificity for guiding *O*-glycosylation has not been determined although it is presumed that folding and solubility of the protein play important roles in the position and number of *O*-linked glycans that occur on a given protein. Mammalian *O*-glycosylation is complex due to a variety of enzymes involved in multiple pathways resulting in a broad range of possible *O*-linked glycoforms. The most common form of human *O*-glycosylation occurs in the Golgi compartment and involves the transfer of a GalNAc residue from UDP-GalNAc to a Ser or Thr through the action of a GalNAc transferase followed by the subsequent transfer of any number of different sugars in different linkages including galactose, GalNAc and GlcNAc. Branching of the *O*-GalNAc chain, as well as the addition of lactosamine, also occurs providing additional oligosaccharide diversity [4]. The *O*-linked glycan chains can also be capped with sialic acid [5]. Different types of *O*-glycosylation (*e.g.*, *O*-linked fucose, glucose, mannose, xylose, or GalNAc) have been described on secretory proteins in mammals [6]. A class of *O*-linked glycosylation in mammals involving *O*-linked mannosyl species has been observed in brain, peripheral-nerve, and muscle glycoproteins [7]. The most well-studied of these, α-dystroglycan, is a heavily glycosylated extracellular membrane glycoprotein that functions to regulate important interactions with extracellular matrix proteins [8]. *O*-mannosylation on α-dystroglycan plays a critical role in normal physiology as

CHAPTER 6

Antibody Engineering through Fc Glycans for Improved Therapeutic Index

Qun Zhou* and **Huawei Qiu**

Protein Engineering, Sanofi, 5 Mountain Road, Framingham, MA 01701, United States

Abstract: The N-glycans from Asn-297 site (or N297 glycans) of antibodies play important roles in antibody function. There is enhanced antibody-dependent cellular cytotoxicity (ADCC) with antibodies containing non-fucosylated glycans, while high anti-inflammatory activity was observed with the antibodies having highly sialylated biantennary structure. Many different approaches have been applied to engineer the N297 glycans with various structures to improve therapeutic efficacy by increasing antibody function, including pro-inflammatory effector function for cancer or antiviral therapy and anti-inflammatory activity for autoimmune diseases. Furthermore, the involvement of various N297 glycan forms in antibody structure-function relationship has also been recently elucidated. The crystal structures of FcγRIIIA complexed with non-fucosylated Fc demonstrated a more favorable carbohydrate-carbohydrate interaction, which is required for high affinity binding and enhanced ADCC activity. The strong anti-inflammatory activity of highly sialylated antibody is related to its interaction with dendritic cell specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN). In addition, the N297 glycans were also remodeled for site-specific antibody conjugation. Thus, antibody glycoengineering provides valuable approaches for modulating antibody function, leading to increased therapeutic index.

Keywords: ADCC, Anti-inflammatory activity, Antibody-dependent cellular cytotoxicity, Autoimmune diseases, Bisecting GlcNAc containing glycans, Cancer, CDC, Complement-dependent cytotoxicity, Dendritic cell specific intercellular adhesion molecule-3-grabbing nonintegrin, FcγRIIIA, Glycoengineering, High mannose-type glycans, Highly galactosylated glycans,

* **Corresponding author Qun Zhou:** Protein Engineering, Sanofi, 5 Mountain Road, Framingham, MA 01701, United States; Tel/Fax: 508-270-2599; E-mail:qun.zhou@sanofi.com

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

Highly sialylated glycans, Homogeneous and site-specific ADC, N-glycans, N297 glycans, Non-fucosylated glycans, Site-specific antibody conjugation, Therapeutic antibodies.

INTRODUCTION

The antibody (or immunoglobulin) belongs to a family of major serum glycoproteins produced by humoral immune system. Its function includes recognition of specific antigens (pathogens) to facilitate their neutralization or killing by other effector cells or serum complements. Among antibodies, IgG is the main isotype. It contains two identical heavy (H) and two identical light (L) chains in a Y-shape, which are held together by a combination of non-covalent interactions and covalent interchain disulfide bonds. Each IgG has Fc and Fab regions, in which two Fab arms contain complementarity-determining regions critical for high affinity interaction with the antigens. The Fc region containing C_H2 and C_H3 is important in binding to either Fcγ receptors (FcγRs) on effector cells or complements for killing pathogens, as well as in the interaction with FcRn for long serum half-life.

The antibody IgG also contains the highly conserved Asn-297 (N297) site with attached N-glycans located in central cavity. In contrast to those found in most glycoproteins, the N297 glycans in C_H2 domains of recombinant therapeutic antibody are only partially processed with core fucosylated biantennary complex-type structures containing zero or one galactose at non-reducing terminus as major species (G0F or G1F). Other glycans, such as the processed sialylated biantennary complex-type, or less processed high mannose-type forms are also present, but at much lower levels. This unique feature is likely due to the low accessibility of N297 glycans inside the C_H2 domains toward galactosyltransferase or sialyltransferase in Golgi apparatus of the cells even when the IgG Fc molecule is in "open" conformation [1].

Although relatively simple compared to those found in other glycoproteins, the N297 glycans play a critical role in antibody structure and function. When the glycans are absent, there are significant structural changes in Fc region, which switches from "open" to "closed" conformation [1]. The binding of aglycosylated

antibodies to FcγRs and complements was abolished with reduced antibody effector function, including antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) [2]. Antibody glycosylation also plays a critical role in stability [2]. Reduction in thermostability of antibodies was observed through sequential deglycosylation.

In addition, there were changes in N297 glycans under certain physiological or pathological conditions [3 - 12]. The glycan profiles vary with age and pregnancy [13]. The glycosylation of antibody is often altered in multiple diseases, especially the autoimmune diseases (Table **1**).

Table 1. The autoimmune disease associated alteration in N-glycans in antibody IgG in serum except those noted in multiple sclerosis.

Disease	Fucosylation	Galactosylation	Sialylation	Bisecting GlcNAc
Rheumatoid arthritis		↓ [9, 14 - 17]		
Osteoarthritis		↓ [17]		
Systemic lupus erythematosus	↓ [18]	↓ [18]	↓ [18]	↑ [18]
Ulcerative colitis		↓ [2]		↑ [2]
Crohn's disease		↓ [2]	↓ [2]	
Kawasaki disease			↓ [19]	
Guillain-Barre syndrom		↓ [12]	↓ [12]	
Multiple sclerosis	↑* [3, 11]	↓* [3, 11]		↑* [3, 11]
Lambert-Eaton myasthenic syndrome and myasthenia gravis		↓ [20]		
Coeliac disease		↓ [21]		
Granulomatosis with polyangiitis		↓↓** [11, 22]	↓** [11, 22]	↓** [22]
Microscopic polyangiitis		↓ [22]		

*: IgG in cerebrospinal fluid.

**: Disease associated autoantibody, anti-proteinase 3.

There are lower galactosylation and sialylation in the patients with those diseases than the control. However, it is unknown whether these changes are related to the mechanism of the disease. With significant progress made during last two decades in developing therapeutic antibodies for treatment of multiple diseases, including cancer and autoimmune diseases, the role of N297 glycans in recombinant

Recent Advances in Biotechnology, 2016, *Vol. 3*, 172-208

CHAPTER 7

Engineering of Therapeutic Proteins through Hyperglycosylation

Natalia Ceaglio*, **Marina Etcheverrigaray, Ricardo Kratje** and **Marcos Oggero**

UNL, CONICET, Cell Culture Laboratory, FBCB. Edificio FBCB-Ciudad Universitaria UNL, C.C. 242. (S3000ZAA) Santa Fe, Argentina

Abstract: One of the major challenges associated with the development of protein-based biotherapeutics lies in achieving persistent concentrations of the active molecule in circulation. Most human proteins are rapidly cleared from circulation, mainly by renal filtration, and so increasing their *in vivo* residence time to reach appropriate therapeutic doses has been a matter of extensive investigation. The majority of therapeutic proteins exhibit post-translational modifications (PTMs). Among them, N- and O-glycosylation are the most abundant and complex modifications that proteins can undergo, affecting diverse biological properties, including solubility, protease and thermal stability, antigenicity, immunogenicity, bioactivity and pharmacokinetics. Thus, glycosylation represents one of the most relevant attributes of many therapeutic proteins, defining their potency and effectiveness. Also, both size and charge of proteins are completely modified by the presence of glycans, so that manipulation of this PTM represents a valuable tool to alter the pharmacokinetics and pharmacodynamics of biotherapeutics. This chapter deals with different glycoengineering strategies developed with the aim of increasing the plasma half-life of proteins, as well as other properties. Specifically, engineering of proteins through the addition of new glycosyl moieties is addressed. A thorough description of the properties conferred to proteins by glycans is first presented, followed by a description of the strategies developed for the rational manipulation of glycosylation parameters to improve such properties. Different approaches to incorporate new N- and O-glycans

* **Corresponding author Natalia Ceaglio:** UNL, CONICET, Cell Culture Laboratory, FBCB. Edificio FBCB-Ciudad Universitaria UNL. C.C. 242. (S3000ZAA) Santa Fe. Argentina; Tel/Fax: +54 342 4552928; E-mail: nceaglio@fbcb.unl.edu.ar

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

into proteins are described and exemplified. Finally, the application of N- and O-hyperglycosylation engineering to an emblematic protein such as recombinant human IFN-α2b is presented.

Keywords: Antigenicity, Bioactivity, Biotherapeutics, CTP, Efficacy, Glycoengineering, Glycosylation prediction, hCG, hEPO, hFSH, hIFN-α2b, Immunogenicity, N-glycosylation, O-glycosylation, Peptide fusion, Pharmacokinetics, Plasma clearance, Site-directed mutagenesis, Solubility, Stability.

INTRODUCTION

In the last decades there has been an accelerated development of protein-based biotherapeutics which have revolutionized the treatment of numerous diseases due to their high specificity and affinity towards its clinical target. Unfortunately, most proteins do not behave as ideal drugs, since their efficacy is compromised by several intrinsic limitations. These include the low *in vivo* activity displayed due to their low stability and short serum half-life, which represent the main obstacles to overcome in order to achieve a successful application as therapeutics [1 - 3]. Thus, many approaches have been developed with the aim of improving the residence time of proteins in circulation to reach appropriate therapeutic doses, as well as to improve other physicochemical and pharmacological properties [4, 5].

The mechanisms involved in plasma clearance of proteins are diverse [6]; however, the most commonly employed route is renal filtration. The structural and physicochemical characteristics of the glomerular barrier are responsible, to a great extent, of the elimination mechanisms. Small molecules are rapidly filtrated through the numerous small 4-10 nm diameter pores, while negatively charged glycosaminoglycans form an anionic barrier which selectively prevents the passage of macromolecules according to their charge. Another site of metabolism of biologics is the liver, where hepatocytes participate in their metabolism through receptor-mediated membrane transport and lysosomal degradation. In addition, peripheral blood-mediated elimination by proteolysis contributes to a great extent to the catabolism of administered proteins [7]. Thus, the structure and size of a protein, represented by its hydrodynamic ratio, as well as its physicochemical

properties constitute starting points for improvement of its plasma half-life.

The majority of proteins derived from eukaryotes undergo covalent modifications either during or after their ribosomal synthesis. This gives rise to the concept of co-translational and post-translational modifications (PTMs). Glycosylation is the most abundant and complex PTM among eukaryotic cells. It constitutes an enzymatic process in which oligosaccharide chains are covalently attached to the amide nitrogen of an asparagine side chain (N-glycosylation) or to oxygen of a hydroxyl group of serine or threonine residues (O-glycosylation), although other types of glycosylation have been described [8, 9]. More than 50% of human proteins are glycoproteins and it is estimated that 1-2% of genome includes genes related to glycan synthesis. Also, glycosylation represents one of the most relevant attributes of many therapeutic proteins, defining their potency and effectiveness [10, 11]. Both size and charge of proteins are completely modified by the presence of glycans, so that manipulation of this PTM represents a valuable tool to alter the pharmacokinetics and pharmacodynamics of biotherapeutics [12]. Thus, engineering of proteins through the addition of new glycosyl moieties has emerged as an area of great technological interest.

PROPERTIES CONFERRED TO PROTEINS BY GLYCANS

There are many theories about the roles of carbohydrates in different types of glycoconjugates, but none of them has demonstrated to be of universal application [13]. Oligosaccharides play a marked effect over diverse biological properties of the glycoproteins, including solubility, stability (regarding protease resistance and thermal degradation), antigenicity, immunogenicity, bioactivity, cell interaction, pharmacokinetics and plasma half-life [14].

Effects of Glycosylation on Solubility and Stability of Glycoproteins

Oligosaccharides often promote protein solubility and prevent protein aggregation. For example, complete removal of O-glycans of human granulocyte colony-stimulating factor (hG-CSF) resulted in a high level of autoaggregation, which led to its biological inactivation [15]. Besides, glycans could contribute to the increment of solubility of proteins through masking exposed hydrophobic amino acid residues.

SUBJECT INDEX

A

Activity 6, 7, 39, 46, 47, 49, 61, 91, 102, 111, 113, 115, 119, 123, 130, 177, 184, 186, 191, 195, 197
antiproliferative 195, 197
antithrombin 46
broad-spectrum 39, 49
ADCC activity 26, 142, 152, 155
enhanced 142, 152
ADCC enhancement 155, 158
ADCC enhancement in non-fucosylated antibodies 157
Addition of N-glycans 180, 182
Aglycosylated Fc 137
All-trans retinoic acid (ATRA) 77
Amino acid residues 182, 183, 184, 185
Aminodextran 78
Amino group of OVA 121, 122
Analysis, theoretical 183, 192, 193
Antibodies 3, 4, 8, 10, 11, 13, 18, 19, 20, 22, 23, 24, 26, 27, 28, 60, 65, 117, 118, 133, 134, 141, 143, 152, 153, 154, 155, 156, 158, 159, 160, 161, 162, 163, 164, 175, 176, 178, 182
anti-CCR4 159
anti-CD22 163
anti-CD30 162
anti-EPO 176
anti-glycan 27
anti-TF 26
bispecific 23
chimeric 26
effective 23
glycan-containing 155
glycoengineered 164
last-mentioned 24
natural 176
next-generation 134
non-conjugated 118
nonfucosylated 158, 159
producing 158
radiolabeling 163
recombinant 141, 158, 182
sialylated 152
Antibodies effector functions 23
Antibodies features, intrinsic 23
Antibodies isotypes 10
Antibodies production 22
Antibody conjugation 152, 153, 161
Antibody-dependent 22, 130, 133, 141, 152, 154, 155, 156, 157, 159
cellular cytotoxicity (ADCC) 22, 130, 141, 152, 154, 155, 156, 157, 159
cellular phagocytosis (ADCP) 133, 141
Antibody-drug 23, 153, 161, 162, 163
conjugates (ADC) 23, 153, 161, 162, 163
conjugation 161, 162
Antibody function 141, 152, 155, 156
Antibody glycoengineering 152, 155, 162, 163
Antibody glycosylation 154, 155
Antibody IgG 153, 154
Antibody molecule 162
Anticancer drug 102, 106, 161, 162, 163, 164
Anticancer vaccines 11, 12, 13, 17, 18, 21
carbohydrate-based 18
Anti-carbohydrate antibodies 23
Antigen binding 142, 143
fragment 142
Antigen-binding affinity 142, 143
Antigens 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 16, 17, 18, 19, 21, 22, 23, 24, 26, 28, 121, 124, 153, 155, 159, 162
associated 23, 28
foreign 121
glycan 24
native 19, 21
pan-carcinoma 8
target 12, 13, 21, 22
Anti-inflammatory activity 152, 156, 157, 159, 160, 164
Anti-proteinase 154
Anti-STn antibodies 7, 9, 14
Anti-Tn antibodies 8
Anti-TNF-α 102, 117, 118
Antiviral protein OAS 116
Antiviral target 45
Asialoglycoprotein 137
Asialoglycoprotein receptor 65, 67, 81, 83, 85, 91, 137, 177

Qun Zhou (Ed.)
All rights reserved-© 2016 Bentham Science Publishers

Asn-substituted residueb 193, 194
Associated cancer antigen analogs 19

B

Bifunctional PEG 83, 84, 85
Biosynthesis of O-glycan chains 5
Block copolymer 83, 87
Breast cancer 8, 15, 107
Broad-spectrum antiviral therapy 39
Bubble lipoplexes 90, 91
Burn progression 117, 118
Butyric acid 106

C

Cancer cells 4, 5, 7, 11, 12, 13, 14, 17, 18, 20, 22, 23, 25, 26, 27, 71, 72, 77, 82, 89, 109, 111, 122
  breast 20
  clear patient's 4
  colon 7
  hepatic 77
  human 25, 111
  human colon 25
  human liver 82
  prostate 26
Cancers 16, 18, 107, 109, 110
  ovarian 107, 109, 110
  peritoneal 16, 18, 107
Cancer therapy 23, 26
Carbohydrate addition 182, 183
Carbohydrate antigens 3, 9, 10, 12, 13, 17, 18
  associated 18
  containing tumor-associated 12
  tumor-associated 13
Carbohydrate-protein contacts 158
Carbohydrates 3, 4, 9, 10, 11, 12, 17, 20, 23, 27, 60, 63, 64, 65, 68, 71, 83, 133, 134, 139, 164, 174, 175, 179, 180, 182, 187
  associated 4, 9, 12, 17
  containing 179
  lack 179, 180
Carbohydrates antibodies 176
Carbohydrates antigens 12
Carboxylic groups 86, 108, 110, 112, 113, 115, 117
Carboxyl-terminal peptide (CTP) 173, 189, 190, 191, 196, 197
Carboxymethyldextran 75, 79
Carcinomas 3, 5, 8
CD44 receptors in cancer cells 109
Cell activation 9, 10
Cell death 22, 23
Cell migration 102, 105
Cell responses, protein abrogates Th1 10
Cells 6, 7, 9, 10, 11, 12, 13, 23, 25, 40, 45, 65, 71, 78, 83, 85, 89, 90, 103, 109, 110, 122, 133, 140, 141, 152, 153, 155, 157, 158, 160, 175, 176, 178, 181
  cancerous 71
  dendritic 10, 141, 152, 160
  hepatoma 83, 85, 89
  insect 158, 178
  natural killer 9, 10, 133
  plant 133, 178
Cell surface 8, 27, 40, 46, 47, 122, 141
Cellular glycans 39, 41, 42, 43, 46, 48
  viral attachment to 42, 46, 48
Chains, oligosaccharide 174, 175, 184
Chebulagic acid 46
Chinese hamster ovary (CHO) 130, 140, 158, 176
Chitosan 75, 76, 77, 109
CHO cells 140, 158, 159, 162, 178, 182, 191, 192
CHO-generated proteins 141
Chronic lymphocytic leukemia (CLL) 159
Cisplatin 107, 112
Collagen antibody-induced arthritis (CAIA) 161
Complement-dependent cytotoxicity (CDC) 22, 141, 152, 154, 155, 156, 157
Complete Freund's adjuvant 17, 20
Complex-type *N*-glycans 139, 179
Consensus tripeptides 183, 184, 186
Constructs 19, 20
  fluorinated 20
  synthetic 19
COSMC gene 6
Covalent conjugation 65, 72
CTP-fused proteins 191
Curdlan backbone 81, 82
Cytokines 10, 13, 116, 118, 176, 184, 192, 194, 196, 197

wild-type 194, 197
Cytotoxicity 10, 22, 141, 152, 154
complement-dependent 141, 152, 154
dependent 10, 22
Cytotoxic T lymphocytes (CTLs) 121, 122, 159

D

Darbepoetin 138
Dendritic cells (DCs) 10, 11, 141, 160
Detection, fluorescence 135
Developed murine antibodies, initial 22
Development of anti-carbohydrate antibodies 23
Dextran 75, 77, 78, 79, 142
Disialylated biantennary glycan 160, 161
Doxorubicin 88, 102, 107, 111, 163
Drug conjugates 102, 108
Drug-linkers 162, 163
conjugating anticancer 162
Drug loading 110, 111, 112
Drug release 109, 110
Drugs, recombinant glycoprotein 134
Dual-affinity re-targeting (DART) 23

E

Effector cells 22, 141, 153, 155
immune 22
Effector macrophages 160
Effects of glycosylation on bioactivity of glycoproteins 175
Efficacious glycoprotein biopharmaceuticals 130
Efficacy of recombinant protein-based therapies 177
Emblematic case 191, 192
Endocytosis 83, 105, 122
Enterovirus 42, 44
Enzymatic degradation 19, 20, 75
Enzymatic glycosylation of O-GlcNAc in glycoproteins 70
Epidermal growth factor (EGF) 47, 113
Epithelial ovarian 16
Ethylene glycol 79, 85, 86
Expressing N-glycans 178
Expression of Thomsen–Friedenreich Antigens in Cancers 8
Extension muteins 186

F

Fab glycans 143
Fallopian tube 16, 18
Fc for Fc-fusion proteins 139
Fc-fusion proteins 130, 139
Fcγ receptors 141, 142, 153
FcγRIIIA, human 157, 158
FcγRIIIA binding 155, 159
Fc protein backbone 158
Fc region 22, 133, 153, 155
Fluorescence detection (FD) 135
Fluorinated STn antigen conjugates 20
Fucosylated biantennary 153, 156
Fucosylated Fc 157, 158
Fucosyltransferase VIII 155, 159
Functionalized PEG 62, 63
Fusion partner 139
Fusion-proteins 140

G

GAG-binding proteins 40
distinct 40
GAG-binding proteins interact 40
Galactose 5, 40, 65, 68, 83, 84, 88, 132, 142, 153, 156, 157, 162, 163, 181
zero 156
Galactosylated PEG strands 83, 84
Galactosyltransferase 66, 68, 153, 162, 163
GalNAc derivatives 163
Gene delivery 60, 65, 75, 80, 82, 85
Gene materials 77
Generation antibodies 22
Gene therapy 60, 65
Glycan-based vaccines 4
Glycan chains 184, 185
Glycan content 177, 180
Glycan delivery 60, 71
Glycan-dependent protein quality control cycle 132
Glycan mimetics 39, 45
Glycan/peptide epitopes 27

Glycan release 130
Glycans 7, 12, 27, 39, 40, 45, 47, 65, 68, 135, 136, 139, 141, 142, 152, 153, 154, 155, 156, 158, 159, 160, 162, 163, 172, 174, 175, 176, 177, 178, 181, 185, 188, 191, 198
  antibody 159, 163
  galactosylated 152
  non-fucosylated 152, 153
  sialylated 153, 159
Glycan STn antigen 26
Glycan structure 40, 132, 156, 157, 179, 181, 190, 191
  monoglucosylated 132
Glycan types 137
Glycation of proteins 68
Glycoengineered non-fucosylated antibodies 159
Glycoengineered therapeutic antibodies 133
Glycoengineering of cells for IgG1 expression 133
Glycoengineering strategy 172, 179, 192
GlycoPEGylation 60, 63, 66, 68, 91
Glycopeptides 12, 17, 21, 47, 135
Glycopolymers 45, 47
Glycoprotein analysis 143
Glycoprotein gC 43
Glycoprotein production systems 133
Glycoproteins 4, 5, 14, 25, 27, 41, 43, 46, 70, 71, 130, 132, 133, 134, 135, 136, 137, 139, 140, 143, 153, 164, 174, 175, 176, 177, 178, 179, 180, 182, 198
  amino acid 139
  clear 137
  complex 135
  extracellular 27
  folded 132
  given 5
  glycosylated extracellular membrane 132
  glycosylation analysis of 134
  injected 176
  intact 135
  low molecular mass 176
  major serum 153
  mammalian 178
  membrane 4
  monomeric-STn 27
  muscle 132
  plant-derived 178
  prevented HSV-1 46
  reactive tumor-associated 25
  therapeutic 133, 143
  viral 41
Glycosaminoglycans 39, 40, 176
Glycosylated forms 137
Glycosylated proteins 176, 177
  natural 176
Glycosylation 18, 66, 130, 131, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 154, 172, 173, 174, 175, 176, 177, 178, 179, 181, 182, 183, 184, 189, 92, 193, 194, 195
  efficiency 181, 182, 184
  machinery 178, 181
  on bioactivity of glycoproteins 175
  parameters 172, 177
  patterns 140, 194
  prediction 173, 189
  profile 134, 141, 195
  sites 18, 134, 135, 138, 142, 181, 193
Glycosyltransferases 5, 180, 188

H

HA-binding proteins 105
HA–Exendin-4 conjugate 114
HA-OVA conjugate 121, 122
HA-Protein Conjugates 115
HA-PTX conjugates 109, 110
HCV E2 protein 43
Hemophilia 67
Heparan sulfate (HS) 39, 40, 41, 42, 43, 44, 45
Heparan sulfate proteoglycans 39
Heparin 39, 43, 45
Heparin-binding domain 43
Hepatitis 39, 41, 49, 64
Hepatitis B virus (HBV) 39, 41, 42, 46, 48
Hepatitis C virus (HCV) 39, 41, 42, 46, 48, 64
Hepatocytes 65, 81, 84, 85, 88, 173, 177
High concentrations 162
High mannose-type glycans 152, 155, 158
High performance liquid chromatography (HPLC) 130, 135
High titers of IgG1 antibodies 17
HIV glycoprotein gp120 43

Hormones, heterodimeric glycoprotein 190
HPV L1 protein 43
HS- and SA-binding virion glycoproteins 48
HS- and SA-binding viruses 48
HS-binding viruses 43, 44, 45, 46, 48
HS-dependent viruses 45, 47
HS mimetics 45, 46
HSV-1 glycoprotein 43
Human colonic cancer cells LS 25
Human cytomegalovirus 41, 42
Human embryonic kidney (HEK) 140
Human growth hormone 102, 190
Human herpesvirus 41, 42
Human immunodeficiency virus (HIV) 39, 40, 41, 42, 45, 48
Human serum albumin (HSA) 68, 69
Human single chain antibodies 24
Hyaluronic acid 40, 77, 102, 103, 104, 121
Hydrogen bonding 41, 44, 48, 77
Hydrogen bonds 44, 45
  forms 44
Hydroxyl-activated ROP 73
Hydroxyl groups 44, 66, 78, 107, 110, 113, 135, 174, 182

I

IgG, glycan-hydrolyzed 161
IgG1 antibodies 17
IgG3 antibodies 137
IgG antibodies 10, 12, 14, 20, 21
  high-affinity 10
IgG molecules 23, 137, 139
IgM antibodies 10, 18, 20
Immune responses 3, 4, 9, 10, 11, 12, 13, 14, 17, 19, 20, 21, 27, 65, 176
  cell-mediated 14
  humoral 9, 10, 176
  selective 17, 19, 20
  strong 11, 19, 20, 21
Immune suppression 9
Immune system 9, 12, 21, 22, 23
Immune thrombocytopenic purpura 160, 161
Immunogenicity 12, 19, 20, 21, 22, 23, 61, 75, 91, 130, 133, 172, 173, 174, 175, 176, 178
Immunological memory 4, 20
Immunological surveillance 11
Influenza A virus (IAV) 42, 44, 47, 48
Inhibitors, molecule entry 39, 40, 49
Intact glycoprotein profiling 135
Interactions 45, 152, 158, 160
  carbohydrate-carbohydrate 152, 158
  carbohydrate-protein 160
  multivalent 45
Intercellular adhesion molecule-3-grabbing nonintegrin 152
Interferon alpha 102, 116
Invasive ductal carcinomas (IDC) 8

J

Jurkat cells 26

K

Ketogalactose 70
Keyhole limpet hemocyanin (KLH) 11, 13, 14, 15, 16, 18, 25

L

Lactobionic acid 77, 86, 87
Layer-by-layer (LbL) 109
Linked disialylated biantennary 156

M

Major histocompatibility complex (MHC) 9
Mammalian cells 137, 178, 183, 188
Mannosylated liposome 90, 91
Mass spectrometry (MS) 65, 130, 135
Merkel cell virus 41, 42, 44
Metastatic breast cancer 13, 14, 15
Microheterogeneity of glycoforms 181, 183
Mimetic vaccines 4, 18
Minocycline hydrochloride (MH) 80
Modifications 46, 65, 66, 68, 82, 113, 116, 116, 121, 131, 133, 136, 172, 174, 178, 183, 186, 189
  chemical 46, 66, 68, 82
  conserved protein 186
  post-translational 65, 131, 133, 136, 172, 174
  random 113, 116
Mogamulizumab 133, 159

Molecular chaperone 6
Molecular masses 176, 193, 196
Molecular mass standards 194, 197
Molecular weights, high 113, 117, 118
Molecules 13, 22, 26, 39, 45, 48, 64, 66, 122, 140, 155, 173, 186, 191
Monoclonal antibodies 4, 24, 130, 133, 136, 141
  humanized 133
Monocytes 141, 157
Monosaccharides 5, 132, 162, 180, 188
MS analyses 135, 136
MUC1 glycopeptide 19, 21
Mucin O-glycan chains 5
Multiantigenic vaccines 17
Multiarm PEGs 60, 62
Multiple sclerosis 154
Multi target antigen-binding 23
Mutagenesis, site-directed 173, 182, 183, 185

N

N-acetyl-glucosamine 5, 157
N-acetyl group 41, 44
N-acetyl-neuraminic acid 5
Native glycoproteins 64, 68
Natural killer (NK) 9, 10, 133, 141
N-2-azidoacetylgalactosamine 70
N-glycan oligosaccharide structures 181
N-glycans 133, 136, 142, 152, 153, 154, 179, 188
N-glycolylneuraminic acid 140, 141
N-glycosylation 131, 141, 173, 174, 180, 182, 183, 184, 185, 186, 187, 189
  consensus tripeptides for 183, 186
N-glycosylation sites 138, 179, 181, 182, 184, 185, 186, 192, 193, 194
  new 179, 185
  potential 181, 192, 193
NHS-ester 64
NK cells 155, 157
N-linked glycosylation 40, 131, 142
N-linked glycosylation sites 142
Non-fucosylated antibodies 155, 156, 157, 158, 159
  generating 158
  increased binding of 157, 158
  producing 158
  sialylated 156
Non-fucosylated 152, 156, 157, 158
  biantennary 156
  bisected biantennary 156, 157
  Fc 152, 157, 158
Novel antibodies, developing 3
Novel erythropoiesis stimulating protein 179, 184
N-terminal elongations 186

O

Obinutuzumab 133, 159
O-GlcNAc quantification 60
O-glycanase 135, 136
O-glycan branch formation 6, 7
O-glycan chains 5, 7
O-glycan chains in cancer cells 4
O-glycan location 188
O-glycans 3, 4, 5, 6, 8, 68, 136, 172, 174, 179, 186, 187, 188, 189
  complex 8
  mucin 4
  short 3
O-glycan synthesis 187
O-glycoproteome 187
O-glycosylated proteins 70
O-glycosylation 6, 132, 173, 174, 186, 187, 189, 196, 198
  mucin-type 186, 189
O-glycosylation probability 189, 196
O-glycosylation sites 60, 63, 138, 179, 185, 189, 191, 192, 196
  potential 189
Oligomannose 135, 157
Oligosaccharides 135, 174, 175, 176, 179, 180, 181
O-linked carbohydrate antigens 4
O-linked glycans 41, 132, 187, 190
O-linked glycosylation 131, 132
O-linked N-acetylglucosamine units in glycoproteins 70
O-linked oligosaccharides 180, 190
Osteoarthritis 102, 113, 114, 120, 123, 154
Ovalbumin 121
Over-expression of Tn antigen 8

Ovine submaxillary mucin (OSM) 25

P

Paclitaxel 64, 102, 106, 107, 109, 110
P-aminophenyl-α-D-mannopyranoside 89
P-aminophenyl glycoside 83, 84
PEG amine 72
PEG derivatives 62
PEG-Intron 64, 116
PEG polymers 75, 77
PEG-sialic acid 60, 66, 67
PEGylated carbohydrates 60, 63
PEGylated glycoproteins 71
PEGylated nanoparticles 60
PEGylated polysaccharides 60, 75
PEGylated proteins 63, 138
PEGylation 61, 62, 63, 64, 66, 67, 68, 69, 70, 71, 72, 75, 76, 77, 83, 91, 131, 138
PEGylation method for proteins 66
PEGylation of native glycoproteins 68
PEGylation of proteins 60
Pentavalent construct 18
Peptide backbone 66, 179, 187, 189
Peptide fusion 173
Peptides 9, 10, 46, 102, 103, 106, 112, 113, 114, 115, 139, 185, 186, 189, 190
  carboxyl-terminal 189, 190
  conjugated 114, 115
  derived 9, 10
  free 114
Peptide substrate specificities 187, 189
Periodate 68, 162
Permethylation 135, 136
P-Nitrophenyl carbonate ester 64
Polycarboxylates 46
Polyethylene glycol 60, 88, 103, 138
Polyethylenimine 85, 86
Polymer conjugate, tumor-targetable 121
Polymer-drug conjugates 103
Polymeric backbone 115, 116, 117, 121
Polymer-protein/peptide conjugates 103
Polymer therapeutics 103
Polypeptide N-acetylgalactosaminyltransferases 6, 187
Post-translational modifications (PTMs) 136, 172, 174
Prostate cancer 16, 18
Proteases 112, 135, 155, 172, 198
Protein A-binding sites 137
Protein activity 116
Protein aggregation 162, 174
  showed low 162
Protein amino groups 63
Protein-based biotherapeutics 172, 173
Protein bioactivity 121, 180
Protein carrier 106
Protein concentrations, higher 131
Protein conjugation, selective N-terminal 118
Protein context 176
Protein coupling 117
Protein drugs 131
Protein extraction 117
Protein folding, lectins support 132
Protein folding events 187
Protein fragments 121
Protein glycoengineering 189
Protein glycoforms 142
Protein glycosylation 177, 187
Protein-protein interaction, strong 160
Proteins 8, 19, 20, 25, 40, 41, 43, 44, 60, 61, 62, 63, 64, 65, 66, 67, 68, 70, 91, 102, 103, 106, 109, 113, 115, 116, 119, 120, 121, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 160, 162, 164, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 188, 189, 190, 191, 194, 195, 196
  administered 173
  altered 66
  anti-fibroblast activation 162
  carrying OSM 25
  conjugated 115
  emblematic 173
  extracellular matrix 132
  fiber shaft 43
  fusion 131
  glycan-bearing 177
  human 140, 172, 174, 176, 179
  human homolog 160
  hyper-N-glycosylated 183
  intracellular 65
  low molecular weight 138
  lymphocyte-associated 140
  mammalian 189

membrane-bound 186
native glycosylated 67
non-glycosylated 63, 195
non-PEGylated 138
purified 138
receptor Fc-fusion 140
saccharide-binding 41
tetanus toxoid 19
viral 44
wild-type 194
xenotypic 141
Proteins-glycoproteins 175
Proteins oligosaccharides 175
Protein solubility 174
Protein stability 139, 177
Protein surface 122
Pulsed amperometric detection (PAD) 130, 135
Punicalagin 46

R

Radix ophiopogonis polysaccharide (ROP) 73, 75
Receptor binding 45, 185, 186
Receptor binding affinities 141, 190
Receptor N162 glycans 158
Receptors 47, 89, 137
glycan 47
mannose 89, 137
Recombinant human erythropoietin 130, 138
Recombinant protein-based therapies 177
Reducing matrix metalloproteinases 113
Regulatory agencies 116, 133, 134, 161
Respiratory syncytial virus (RSV) 41, 42, 43
Rheumatoid arthritis 63, 64, 154

S

SA-binding virion glycoproteins 48
SA-binding viruses 44, 47, 48
Secretory glycoproteins 132
Sendai virus 42, 44
SG-binding proteins 41
SGs and SG-binding proteins 41
Sialic acid-binding viruses 44
Sialic acid content 140, 142
Sialic acid residues 9, 87, 143
Sialic acids 4, 8, 39, 40, 42, 44, 45, 67, 68, 69, 70, 88, 130, 132, 134, 135, 139, 140, 142, 157, 160, 162, 175, 177, 179, 185, 188
introducing new 179
terminal 69, 70, 134, 175, 177
Sialidase 47, 67, 68, 135
Sialoglycans 40
Sialoglycoproteins 68
Sialylated IVIG 160, 161
Sialylation 139, 140, 142, 154, 159, 160
Sialyl mimetics 47
Sialyl-Tn antigens 4
Sialyltransferases 7, 67, 153, 160, 162, 163, 178
Single chain variable fragment 24
Solubility and stability of glycoproteins 174
Specificities, glycan antibodies 27
SPG-graft-PEG copolymer 81
Stability, vivo glycoproteins 175
Stability of glycoproteins 174
Steric entanglement 116, 119, 121
STn breast cancer cells 14
STn-carrying glycoproteins 14
STn-expressing cancer cells 11
STn expression 7, 9
STn in cancer cells 14
Sugar PEGylation 61
Sulfated polysaccharides 45, 46
Synthase 7
Synthesis, glycan 174
Synthesis of Man-PEG-AD 89, 90
Synthetic STn-mimicking antigen 13, 15

T

T-antigen carbohydrate 20
Target cancer cells 10
Targeted drug delivery 86, 87
TC-1 tumor cells 122
Terminal galactose 68, 83, 142, 177
Tetanus toxoid 17, 19, 20, 143
TF antigens 3, 4, 7, 11, 27, 28
TF-based therapeutic antibodies 28
TF-expressing cancer cells 27
Therapeutic antibodies 4, 22, 23, 153, 154, 164
developing 154
effective 164

Therapeutic antibodies in cancer 22
Therapeutic doses 172, 173
Therapeutic efficacy 130, 131, 152, 176
Therapeutic monoclonal antibodies 141
Therapeutic proteins 130, 133
  developing 130
  marketed 133
Therapies 11, 12, 13, 14, 15, 16, 21, 23, 28, 45, 102, 112, 134, 184
  anticancer 102, 112
  biosimilar protein 134
  glycan-targeted antiviral 45
  hormone 14
Thomsen Friedenreich (TF) 3, 4, 13, 18, 27
Thomsen–Friedenreich antigens 4, 5, 8, 13, 24
Threonine 4, 5, 66
Threonine residues 4, 174
Thr residues 132, 183, 186, 187
Thyrogen 68, 69, 70
Tn and STn antigens 5, 10, 23
Tn antigen 4, 5, 6, 7, 8, 10, 19, 25, 26, 187
Tolerance 10, 11, 21
  immune 10, 11
  immunological 11, 21
Transfer reaction, initial glycan 131
Tri-mannose core 155
Tripeptide 182
Trypsin 115, 119
Tumor antigen 18, 24, 25, 161
Tumor cells 4, 8, 9, 10, 12, 13, 14, 17, 19, 21, 23, 26, 109, 110, 121
Tumor glycan signature 23
Tumor Model 106, 107, 157
Tumor progression 11

U

Unimolecular multiantigenic vaccines 17

V

Vaccination 14, 65
Vaccine candidates 12, 13, 17, 18, 19, 20, 21
Vaccines 4, 14, 18, 21
  monoantigenic 14, 18
  self-adjuvanting 4, 21
Vaccines and antibodies 3, 4, 28
Vascular endothelial growth factor (VEGF) 114
Vesicular stomatitis virus (VSV) 41, 45
Viral attachment 39, 40, 42, 43, 45, 46, 47, 48
Virion glycoproteins 39, 43, 44, 45, 46, 47
  binding of 39, 45, 47
Virus 39, 40, 41, 42, 44
  dengue 41, 42
  herpes simplex 39, 41
  human immunodeficiency 39, 40, 41
  influenza 39, 40
  varicella zoster 41, 42